FI943564A7 - Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia - Google Patents

Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia Download PDF

Info

Publication number
FI943564A7
FI943564A7 FI943564A FI943564A FI943564A7 FI 943564 A7 FI943564 A7 FI 943564A7 FI 943564 A FI943564 A FI 943564A FI 943564 A FI943564 A FI 943564A FI 943564 A7 FI943564 A7 FI 943564A7
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
granulocyte colony
stimulating activity
Prior art date
Application number
FI943564A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943564L (fi
FI943564A0 (fi
Inventor
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI943564L publication Critical patent/FI943564L/fi
Publication of FI943564A0 publication Critical patent/FI943564A0/fi
Publication of FI943564A7 publication Critical patent/FI943564A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI943564A 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia FI943564A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9201065A FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
PCT/FR1993/000086 WO1993015211A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant

Publications (3)

Publication Number Publication Date
FI943564L FI943564L (fi) 1994-07-29
FI943564A0 FI943564A0 (fi) 1994-07-29
FI943564A7 true FI943564A7 (fi) 1994-07-29

Family

ID=9426191

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943564A FI943564A7 (fi) 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia

Country Status (8)

Country Link
US (1) US5665863A (enExample)
EP (1) EP0624200A1 (enExample)
JP (1) JPH07503844A (enExample)
CA (1) CA2125979A1 (enExample)
FI (1) FI943564A7 (enExample)
FR (1) FR2686900B1 (enExample)
NO (1) NO942858L (enExample)
WO (1) WO1993015211A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
BR9910568A (pt) * 1998-04-30 2001-09-11 Tanox Inc Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
JP2002534059A (ja) * 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
ATE269716T1 (de) 2000-02-29 2004-07-15 Pfizer Prod Inc Stabilisierter granulozyten-kolonie- stimulierender faktor
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
WO2005034877A2 (en) * 2003-10-10 2005-04-21 University Of Southern California G-csf transferrin fusion proteins
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
BRPI1004940A2 (pt) * 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2737905B1 (en) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US10654912B2 (en) 2015-09-08 2020-05-19 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
EP3431508A4 (en) 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN
US10866963B2 (en) 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
FR2649991B2 (fr) * 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
EP0395918A3 (en) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3

Also Published As

Publication number Publication date
FR2686900A1 (fr) 1993-08-06
WO1993015211A1 (fr) 1993-08-05
FI943564L (fi) 1994-07-29
FI943564A0 (fi) 1994-07-29
EP0624200A1 (fr) 1994-11-17
FR2686900B1 (fr) 1995-07-21
US5665863A (en) 1997-09-09
NO942858D0 (enExample) 1994-08-01
NO942858L (no) 1994-08-01
CA2125979A1 (fr) 1993-08-05
JPH07503844A (ja) 1995-04-27

Similar Documents

Publication Publication Date Title
FI943564L (fi) Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI20010334L (fi) Granulosyyttipesäkkeitä stimuloivia polypeptidejä, niitä sisältävä farmaseuttinen koostumus, ja niiden lääketieteellinen käyttö
FI943565L (fi) Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
NZ218089A (en) 7-piperazinyl, 4-oxoquinolines and pharmaceutical compositions
IT1232677B (it) Composizione farmaceutica contenente ranitidina
FI862479L (fi) Oral farmaceutisk komposition.
IL79323A0 (en) Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
IT8621358A1 (it) Composizione farmaceutica ad attività analgesica
FI844289A7 (fi) Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
ZA89792B (en) Pharmaceutical compositions with improved stability
IT1214683B (it) Composizioni farmaceutiche nasali
FI893643A7 (fi) Farmaseuttisia koostumuksia
IL71951A0 (en) Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
FI943645L (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
NZ217123A (en) 7-alpha-cephalosporins, pharmaceutical compositions and intermediate compounds
DE3674040D1 (de) Pharmazeutische zusammensetzungen.
IT1213453B (it) Composizione farmaceutica.
IT8621393A0 (it) Composizioni farmaceutiche ad azione vasodilatatrice e dantianossica.
IL79469A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
IL79039A0 (en) 4-oxoquinolinesulfonamides,their preparation and pharmaceutical compositions containing them
EE9400337A (et) Alfainterferooni sisaldavad farmatseutilised kompositsioonid ja nende kasutusvõimalused
HUT70031A (en) Alfa, omega-diarylalkane derivatives, their preparation and pharmaceutical compositions containing them
IL78432A (en) Dichloroaniline derivatives,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD Application lapsed